The Effect of Intracavernosal Avanafil, a Newer Phosphodiesterase-5 Inhibitor, on Neonatal Type 2 Diabetic Rats With Erectile Dysfunction

Yilmaz, Didem; Bayatli, Nur; Un, Ozge; Kadowitz, Philip; Sikka, Suresh; GÜR, SERAP

doi:10.1016/j.urology.2013.10.021

The Effect of Intracavernosal Avanafil, a Newer Phosphodiesterase-5 Inhibitor, on Neonatal Type 2 Diabetic Rats With Erectile Dysfunction

Copy For Citation

Yilmaz D., Bayatli N., Un O., Kadowitz P. J., Sikka S. C., GÜR S.

UROLOGY, vol.83, no.2, 2014 (SCI-Expanded)

Publication Type: Article / Article
Volume: 83 Issue: 2
Publication Date: 2014
Doi Number: 10.1016/j.urology.2013.10.021
Journal Name: UROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Ankara University Affiliated: Yes

Abstract

OBJECTIVE To determine the effect of avanafil, a novel phosphodiesterase-5 inhibitor, on the treatment of erectile dysfunction associated with type 2 diabetes mellitus (T2DM).